Core Insights - OSE Immunotherapeutics has announced a strategic realignment of its R&D portfolio, pausing the development of OSE-230 to focus on late-stage assets lusvertikimab (OSE-127) and Tedopi®, which are expected to generate multiple clinical catalysts from 2026 to 2028 [1][3][9] Group 1: Portfolio Realignment - The decision to pause OSE-230 reflects a disciplined evolution of the company's portfolio, concentrating resources on high-potential late-stage programs [3][4] - The company aims to enhance its ability to deliver late-stage clinical progress and secure meaningful partnerships by focusing on its cornerstone assets [3][9] Group 2: Discontinuation of Other Programs - Boehringer Ingelheim has discontinued the development of BI 770371 for MASH after a Phase 2 study showed no efficacy, although the treatment was well tolerated [2][5] - OSE Immunotherapeutics will also discontinue exploratory research on the CLEC-1 program in oncology, aligning its portfolio with late-stage value creation strategies [7][9] Group 3: Expected Clinical Catalysts - OSE Immunotherapeutics has identified chronic pouchitis and hidradenitis suppurativa as new indications for lusvertikimab, with a subcutaneous formulation being developed for ulcerative colitis [8][14] - The company is set to complete the Phase 3 trial for Tedopi® in NSCLC, with multiple key read-outs expected between 2026 and 2028 [14]

Core Insights - OSE Immunotherapeutics has selected chronic pouchitis and hidradenitis suppurativa as new clinical indications for lusvertikimab, aligning with its strategic plan for 2026-2028 to target high-value immune-mediated diseases [2][5] - The development of these indications is contingent on financing, with the first Phase 2 clinical trial expected to start in the second half of 2026 [2][15] Group 1: Indications and Rationale - Chronic pouchitis and hidradenitis suppurativa both show strong translational alignment with IL-7R biology, indicating a significant unmet medical need [3][9] - Chronic pouchitis affects approximately 70% of patients who undergo proctocolectomy for ulcerative colitis, with about 45,000 patients in the EU, North America, and Japan developing chronic pouchitis, highlighting a significant management challenge [6] - Hidradenitis suppurativa affects around 1% of the general population, equating to approximately 9.5 million individuals in the same regions, and is associated with a long diagnostic delay and severe quality of life impacts [7][9] Group 2: Development Strategy - The company aims to leverage the capital-efficient nature of chronic pouchitis as a rare disease opportunity while also pursuing the larger dermatology market for hidradenitis suppurativa [5][10] - The first Phase 2 clinical trial is designed to provide clear evidence of differentiated clinical efficacy and safety, supporting a fast, data-driven proof-of-concept strategy [10][11] - OSE plans to advance the ulcerative colitis indication alongside these new indications, developing a subcutaneous formulation of lusvertikimab to enhance its market potential [11]